Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2020; 26(28): 4140-4150
Published online Jul 28, 2020. doi: 10.3748/wjg.v26.i28.4140
Published online Jul 28, 2020. doi: 10.3748/wjg.v26.i28.4140
Insulin receptor substrate 1 may play divergent roles in human colorectal cancer development and progression
Karolina Lomperta, Malgorzata Grudzinska, Stanislaw Sulkowski, Mariusz Koda, Department of General Pathomorphology, Medical University of Bialystok, Bialystok 15269, Poland
Katarzyna Jakubowska, Luiza Kanczuga-Koda, Department of Pathomorphology, Comprehensive Cancer Centre, Bialystok 15027, Poland
Andrzej Wincewicz, Department of Pathology, Nonpublic Health Care Unit, Kielce 25734, Poland
Eva Surmacz, Allysta Pharmaceuticals Incorporated, Belmont, CA 94002, United States
Author contributions: Lomperta K contributed to data analysis, literature review and writing the manuscript; Kanczuga-Koda L, Koda M and Wincewicz A contributed to data acquisition, data analysis and design of the manuscript; Jakubowska K and Grudzinska M contributed to literature review and manuscript drafting; Surmacz E contributed to editing the manuscript; Surmacz E, Sulkowski S and Koda M performed the revision and approval of the final version; Koda M supervised the project; all authors provided critical feedback and helped shape the research, analysis and manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Medical University of Bialystok, Poland.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Karolina Lomperta, MD, Doctor, Department of General Pathomorphology, Medical University of Bialystok, 13 Waszyngtona Street, Bialystok 15269, Poland. karlomperta@gmail.com
Received: April 30, 2020
Peer-review started: April 30, 2020
First decision: May 15, 2020
Revised: May 26, 2020
Accepted: July 17, 2020
Article in press: July 17, 2020
Published online: July 28, 2020
Processing time: 88 Days and 20.8 Hours
Peer-review started: April 30, 2020
First decision: May 15, 2020
Revised: May 26, 2020
Accepted: July 17, 2020
Article in press: July 17, 2020
Published online: July 28, 2020
Processing time: 88 Days and 20.8 Hours
Core Tip
Core tip: We analyzed the expressions of Insulin receptor substrate 1 (IRS-1), Bax, Bcl-xL and Ki-67 proteins in primary colorectal cancer (CRC). We found that IRS-1 expression was associated with tumor grade and histological type, and was more prevalent in more differentiated CRC. Interestingly, IRS-1 expression was significantly correlated with Bax and Bcl-xL, but not with Ki-67. We hypothesize that coexpression of IRS-1 and proapoptotic and antiapoptotic markers could result in a complex and diverse interplay characteristic for earlier stages in CRC.